Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group. Grebely J, et al. Among authors: weltman m. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6. Lancet Gastroenterol Hepatol. 2018. PMID: 29310928 Free article. Clinical Trial.
Modelling the hepatitis C virus epidemic in Australia.
Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M, Li J, Maher L, McGregor S, Hellard M, Poeder F, Quaine J, Stewart K, Tyrrell H, Weltman M, Westcott O, Wodak A, Law M. Razali K, et al. Among authors: weltman m. Drug Alcohol Depend. 2007 Dec 1;91(2-3):228-35. doi: 10.1016/j.drugalcdep.2007.05.026. Epub 2007 Jul 31. Drug Alcohol Depend. 2007. PMID: 17669601
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.
Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ; Chariot Study Group. Roberts SK, et al. Among authors: weltman md. Hepatology. 2009 Oct;50(4):1045-55. doi: 10.1002/hep.23130. Hepatology. 2009. PMID: 19676125 Clinical Trial.
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. Suppiah V, et al. Among authors: weltman m. Nat Genet. 2009 Oct;41(10):1100-4. doi: 10.1038/ng.447. Epub 2009 Sep 13. Nat Genet. 2009. PMID: 19749758
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.
Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, Yoshihara M, Dore GJ; CHARIOT Study Group. Cheng WS, et al. Among authors: weltman m. J Hepatol. 2010 Oct;53(4):616-23. doi: 10.1016/j.jhep.2010.04.024. Epub 2010 Jun 16. J Hepatol. 2010. PMID: 20619475 Clinical Trial.
133 results